Where does Ran Nussbaum work?

Ran Nussbaum is Managing Partner & Co-founder of Pontifax and Partner at Pontifax Venture Capital and Board director at Kerostx and Board director at Kite Pharma and Board director at Urogen.

What check size does Ran Nussbaum write?

Ran Nussbaum typically writes checks of $10M – $50M.

What boards does Ran Nussbaum sit on?

Ran Nussbaum holds tracked board seats at Graviton Bioscience Corporation, LB Pharmaceuticals, Urogen.

Where did Ran Nussbaum go to school?

Ran Nussbaum studied at ygal alon.

Ran Nussbaum

InvestorFounder

Partner at Pontifax Venture Capital · Board director at Kerostx · Board director at Kite Pharma · Board director at Urogen

Israel

Writes $10M – $50M checks · typically $25M

FoundedPontifax

Find your path to Ran

11 people in our graph share verified history with Ran — schools, employers, funds. One of them is your warm intro.

Asaf ShinarunlockedRan: together at Pontifax (2007–2026)

Ran: together at Pontifax

×9Ran: together at Pontifax Venture Capital

About

Managing partner and co-founder of The Pontifax Group. Has served on boards of numerous biotech companies including Kite Pharma, cCAM Therapeutics, ArQule, Emergence, and Prevail, and currently chairs Graviton, Lutris Pharma, and Adcytherix.

Contact· self-published, not guessed

r•••@pontifax.comreveal

Board director at Kerostx

Intro paths

→

In turn, Ran can intro founders to Kerostx's investors below.

Kerostx's investors · 4

Arkin CapitalHerzliya Foresite CapitalWest Hollywood OrbiMedNew York · $1M – $75M checks · since 2020 Pontifax Venture CapitalHerzeliya · $6.3M – $128M checks

Co-founders at Kerostx

Jasbir S. SeehraExecutive Officer, Director

Jasbir SeehraCo-Founder, Chief Executive Officer and Director

Board director at Kite Pharma

Intro paths

→

In turn, Ran can intro founders to Kite Pharma's investors below.

Kite Pharma's investors · 2

Alta PartnersJackson · $1M – $12M checks · since 2014 Pontifax Venture CapitalHerzeliya · $6.3M – $128M checks · since 2014

Co-founders at Kite Pharma

Arie S. BelldegrunExecutive Officer, Director

Board director at Urogen

Intro paths

→

In turn, Ran can intro founders to Urogen's investors below.

Urogen's investors · 3

Aisling CapitalNew York · since 2023 Monograph Capital PartnersLondon · since 2023 Pontifax Venture CapitalHerzeliya · $6.3M – $128M checks · since 2023

Experience

Pontifaxpartnercurrent2004 — present

Investments

Board seats

Graviton Bioscience Corporation LB Pharmaceuticals Urogen

Per SEC Form D filings.

Colleagues at Pontifax Venture Capital

Asaf Shinar

Director at Pontifax Venture Capital

Lina Kaminski

Principal at Pontifax Venture Capital

Momi Karako

General Partner at Viola Credit

Momi Karako

Investment Professional at Pontifax Venture Capital

Ohad Hammer

Investor at Xtripe Angels

Ohad Hammer

Investment Professional at Pontifax Venture Capital

Pat McClain

Principal, Financial Performance at Five Elms Capital

Tomer Kariv

Chief Executive Officer at Pontifax Venture Capital

Frequently asked questions

Who is Ran Nussbaum?: Managing partner and co-founder of The Pontifax Group. Has served on boards of numerous biotech companies including Kite Pharma, cCAM Therapeutics, ArQule, Emergence, and Prevail, and currently chairs Graviton, Lutris Pharma, and Adcytherix.
Where does Ran Nussbaum work?: Ran Nussbaum is Managing Partner & Co-founder of Pontifax and Partner at Pontifax Venture Capital and Board director at Kerostx and Board director at Kite Pharma and Board director at Urogen.
What check size does Ran Nussbaum write?: Ran Nussbaum typically writes checks of $10M – $50M.
What companies did Ran Nussbaum found?: Ran Nussbaum founded Pontifax.
What boards does Ran Nussbaum sit on?: Ran Nussbaum holds tracked board seats at Graviton Bioscience Corporation, LB Pharmaceuticals, Urogen.
Where did Ran Nussbaum go to school?: Ran Nussbaum studied at ygal alon.

Founder mafias

Pontifax Venture Capital mafia2

Also came through, then founded or led a company.

Marshall GouldVenture InternFounded Juno